<DOC>
	<DOCNO>NCT02501551</DOCNO>
	<brief_summary>This phase II trial regorafenib patient metastatic melanoma harbor c-Kit mutation and/or amplification c-Kit gene copy number . The primary end point disease control rate ( DCR ) , secondary end point safety , response rate ( RR ) , progression free survival ( PFS ) , overall survival ( OS ) .</brief_summary>
	<brief_title>Regorafenib , C-kit Mutated Malignant Melanoma , 2nd Line Therapy</brief_title>
	<detailed_description>The incidence melanoma rise globally mortality increase faster cancer . Recent advance molecular biology melanoma uncover several potential therapeutic target melanoma . It observe 81 % melanoma arise non-chronic sun-damaged skin oncogenic BRAF NRAS mutation , whereas mutation far less frequent chronic sun-damaged skin melanoma , acral melanoma , mucosal melanoma . In contrast , c-Kit mutation common mucosal acral melanoma , also accompanied increase c-Kit copy number . Asian population , common melanoma subtypes acral mucosal melanoma , comprise great 70 % melanoma , rate much high see white population ( 6 % 7 % ) . KIT mutation amplification report 20 % acral mucosal melanoma ( JAMA . 2011 ; 305 ( 22 ) :2327-2334 ) . Therefore , c-Kit mutation likely common kind genetic mutation Asians , investigation c-Kit inhibitor high priority population . Imatinib mesylate ( Gleevec , formerly STI571 ; Novartis Pharmaceuticals , Basel , Switzerland ) , selective inhibitor , target Abl well c-Kit platelet-derived growth factor receptor . Imatinib demonstrate significant activity patient metastatic melanoma harbor genetic c-Kit aberration , overall response rate 29 % ( J Clin Oncol 2011 ; 29:2904-9 ) Regorafenib ( BAY 73-4506 ) novel , orally active , diphenylurea multikinase inhibitor VEGFR1-3 , c-KIT , TIE-2 , PDGFR-Î² , FGFR-1 , RET , RAF-1 , BRAF p38 MAP kinase . Regorafenib provide significant improve PFS OS patient GIST colorectal cancer , respectively ( Lancet 2013 ; 381 : 295-302 , Lancet 2013 ; 381 : 303-12 ) . Especially , inhibitory activity regorafenib effective c-kit mutate tumor . Therefore , regorafenib chance significant activity melanoma c-kit mutation . However , clinical trial publish regorafenib patient melanoma harbor c-Kit mutation . NCCN recommend ipilimumab , high-dose interleukin-2 , vemurafenib dabrafenib BRAF mutate tumor preferred regimen , imatinib c-kit mutate tumor , dacarbazine , temozolomide , paclitaxel active regimen . In Korea , ipilimumab available yet imatinib c-kit mutate tumor use legally . Thus , regorafenib could use c-kit mutated tumor clinical trial setting .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<criteria>1 . Histologically cytologically proven melanoma stage IV unresectable stage III disease 2. ckit mutation 3. performance status 0 , 1 , 2 4 . Have progress 1 previous systemic treatment contain dacarbazine , temozolomide , immunotherapy metastatic melanoma 5 . Patients central nervous system metastasis must stable neurologic function without evidence central nervous system progression within 8 week 6 . Measurable disease nonmeasurable evaluable disease , accord Response Evaluation Criteria Solid Tumors v1.1 1 . Major surgery radiation therapy within 4 week start study treatment 2 . History know carcinomatous meningitis , evidence symptomatic leptomeningeal disease 3 . Have receive great equal 2 previous chemotherapycontaining systemic treatment regimens 4 . Patients BRAF NRAS mutation 5 . Prior therapy ckit inhibitor 6 . Significant history cardiac disease , myocardial infarction , current cardiac ventricular arrhythmia require medication 7 . Major surgery within 4 week start study treatment 8 . Active gastrointestinal bleeding 9 . Patients treat coadministration strong CYP3A4 inducer 10 . Adequate Hematologic , Biochemical , Organ Function</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Malignant melanoma</keyword>
	<keyword>C-KIT mutation</keyword>
</DOC>